China Medical System Holdings Limited
0867
Rang in Aktien
#4740
Established in 1995 and headquartered in North Point, Hong Kong, China Medical... Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
Aktienkurs
$1.30
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.17B
Veränderung (1 Tag)
-2.21%
Veränderung (1 Jahr)
-22.77%
Land
HK
Handel China Medical System Holdings Limited (0867)
Kategorie
Healthcare
Operative Marge für China Medical System Holdings Limited (0867)
Operative Marge zum October 2026 TTM: 19.93%
Laut den neuesten Finanzberichten und dem Aktienkurs von China Medical System Holdings Limited beträgt die aktuelle operative Marge (TTM) 19.93%. Am Ende des Jahres 2023 lag die operative Marge bei 33.85%.
Historie der operativen Marge von China Medical System Holdings Limited von 2006 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 19.93% | -14.09% |
| 2024 | 23.20% | -31.46% |
| 2023 | 33.85% | -12.80% |
| 2022 | 38.82% | 2.73% |
| 2021 | 37.79% | -5.00% |
| 2020 | 39.78% | -8.36% |
| 2019 | 43.41% | 3.53% |
| 2018 | 41.93% | -0.33% |
| 2017 | 42.07% | 21.73% |
| 2016 | 34.56% | -1.00% |
| 2015 | 34.91% | -5.65% |
| 2014 | 37.00% | 3.70% |
| 2013 | 35.68% | -9.46% |
| 2012 | 39.41% | 20.15% |
| 2011 | 32.80% | 22.98% |
| 2010 | 26.67% | -3.23% |
| 2009 | 27.56% | 10.82% |
| 2008 | 24.87% | 24.23% |
| 2007 | 20.02% | 37.31% |
| 2006 | 14.58% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.85% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.